Trial · NCT01173679
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate | Dasatinib, Rituximab, Fludarabine | CR | 2 | Participants | |
| Response Rate | Dasatinib, Rituximab, Fludarabine | PR | 2 | Participants | |
| Response Rate | Dasatinib, Rituximab, Fludarabine | SD | 5 | Participants | |
| Response Rate | Dasatinib, Rituximab, Fludarabine | PD | 1 | Participants | |
| Progression-Free and Overall Survival | Dasatinib, Rituximab, Fludarabine | Progression-free survival | 8.75 | Inter-Quartile Range 2.75 to 13 | months |
| Progression-Free and Overall Survival | Dasatinib, Rituximab, Fludarabine | Overall survival | 24 | Inter-Quartile Range 16.25 to 24 | months |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Platelets / 3 | 4 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Platelets / 4 | 3 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Platelets / 5 | 0 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Platelets / Did not have any | 3 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Neutropenia / 3 | 3 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Neutropenia / 4 | 3 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Neutropenia / 5 | 0 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Neutropenia / Did not have any | 4 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Fatigue / 3 | 1 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Fatigue / 4 | 0 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Fatigue / 5 | 0 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Fatigue / Did not have any | 9 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Dyspnea / 3 | 1 | Participants | |
| Toxicities | Dasatinib, Rituximab, Fludarabine | Dyspnea / 4 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01173679/results